Divis Laboratories surged 5.35% to Rs 6234.50 after a leading foreign brokerage maintained its 'Buy' rating on the stock, setting a price target of Rs 7,050 per share.
In its latest note, the broker highlighted Divis strong potential to emerge as a primary supplier, backed by ongoing capacity expansion. It also noted the addition of OrforglipronEli Lillys promising oral GLP-1 candidateto Divis development pipeline. The report further anticipates additional rounds of capital expenditure as product volumes scale up through 2030.Divi's is engaged in manufacturing of generic APIs, custom synthesis of active ingredients for innovator companies, other specialty chemicals and nutraceuticals. The company is focused on export markets within the domain of its capabilities.
Divis Laboratories' consolidated net profit surged 64.53% to Rs 589 crore on 25.01% rise in revenue from operations to Rs 2,319 crore in Q3 FY25 over Q3 FY24.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app